Pregnancy Outcome After TNF-α Inhibitor Therapy During the First Trimester: A Prospective Multicentre Cohort Study

Br J Clin Pharmacol. 2015 Oct;80(4):727-39. doi: 10.1111/bcp.12642. Epub 2015 May 28.

Abstract

Aims: TNF-α inhibitors are considered relatively safe in pregnancy but experience is still limited. The aim of this study was to evaluate the risk of major birth defects, spontaneous abortion, preterm birth and reduced birth weight after first trimester exposure to TNF-α inhibitors.

Methods: Pregnancy outcomes of women on adalimumab, infliximab, etanercept, certolizumab pegol or golimumab were evaluated in a prospective observational cohort study and compared with outcomes of a non-exposed random sample. The samples were drawn from pregnancies identified by institutes collaborating in the European Network of Teratology Information Services.

Results: In total, 495 exposed and 1532 comparison pregnancies were contributed from nine countries. The risk of major birth defects was increased in the exposed (5.0%) compared with the non-exposed group (1.5%; adjusted odds ratio (ORadj ) 2.2, 95% CI 1.0, 4.8). The risk of preterm birth was increased (17.6%; ORadj 1.69, 95% CI 1.1, 2.5), but not the risk of spontaneous abortion (16.2%; adjusted hazard ratio [HRadj ] 1.06, 95% CI 0.7, 1.7). Birth weights adjusted for gestational age and sex were significantly lower in the exposed group compared to the non-exposed cohort (P = 0.02). As a diseased comparison group was not possible to ascertain, the influence of disease and treatment on birth weight and preterm birth could not be differentiated.

Conclusions: TNF-α inhibitors may carry a risk of adverse pregnancy outcome of moderate clinical relevance. Considering the impact of insufficiently controlled autoimmune disease on the mother and the unborn child, TNF-α inhibitors may nevertheless be a treatment option in women with severe disease refractory to established immunomodulatory drugs.

Keywords: TNF-α inhibitors; birth defects; birth weight; malformations; pregnancy outcome.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abnormalities, Drug-Induced / epidemiology*
  • Abortion, Spontaneous / epidemiology*
  • Adalimumab / adverse effects
  • Antibodies, Monoclonal / adverse effects
  • Birth Weight / drug effects*
  • Case-Control Studies
  • Certolizumab Pegol / adverse effects
  • Etanercept / adverse effects
  • Europe / epidemiology
  • Female
  • Humans
  • Infliximab / adverse effects
  • Pregnancy
  • Pregnancy Outcome / epidemiology*
  • Pregnancy Trimester, First*
  • Premature Birth / epidemiology*
  • Prospective Studies
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha
  • golimumab
  • Infliximab
  • Adalimumab
  • Etanercept
  • Certolizumab Pegol